Role of PPAR- γ agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: A cardiovascular perspective

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 5, 2005, Pages 377-386

  Dumasia, Rupal ^a   Eagle, Kim A ^a   Kline Rogers, Eva ^a   May, Niquole ^a   Cho, Leslie ^b   Mukherjee, Debabrata ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; LIGAND; LIVER ENZYME; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG MECHANISM; FATTY ACID OXIDATION; FLUID RETENTION; HEART MUSCLE ISCHEMIA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LEG EDEMA; LIPID METABOLISM; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG EDEMA; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEINURIA; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; VASCULAR ENDOTHELIUM; WEIGHT GAIN; ZINC FINGER MOTIF;

DIABETES MELLITUS, TYPE 2; HUMANS; PPAR GAMMA; PREDIABETIC STATE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 27744467604     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800605774370362     Document Type: Review

References (27)

1. Henry, R.R. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin. Ther., 2003, 25 Suppl. B, B47-63.
2. Edelman, S.V. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. Rev. Cardiovasc. Med., 2003, 4 Suppl. 6, S29-37.
3. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2004, 27 Suppl. 1, S5-S10.
4. Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002, 288, 2709-2716.
5. Haffner, S.M. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res. Clin. Pract., 2003, 61 Suppl. 1, S9-S18.
6. Yki-Jarvinen, H. Thiazolidinediones. N. Engl. J. Med., 2004, 351, 1106-1118.
7. Reusch, J.E. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am. J. Cardiol, 2002, 90, 19G-26G.
8. Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998, 339, 229-234.
9. Hu, G., Jousilahti, P., Qiao, Q., Peltonen, M., Katoh, S., Tuomilehto, J. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J. Am. Coll. Cardiol., 2005, 45, 1413-1418.
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
11. Otten, R., Kline-Rogers, E., Meier, D., Dumasia, R., Fang, J., May, N., Resin, Y., Armstrong, D., Saab, F., Petrina, M., Eagle, K., Mukherjee, D. Impact of prediabetic state on clinical outcomes in patients with acute coronary syndromes. Heart, 2005, (accepted).
12. Olefsky, J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J. Clin. Invest., 2000, 106, 467-472.
13. Wang, M., Tafuri, S. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J. Cell Biochem., 2003, 89, 38-47.
14. Hsueh, W.A., Jackson, S., Law, R.E. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care, 2001, 24, 392-397.
15. Momoi, A., Murao, K., Imachi, H., Ishida, T., Cao, W.M., Sato, M., Takahara, J. Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione. Chest, 2001, 120, 1293-1300.
16. Panzer, U., Schneider, A., Guan, Y., Reinking, R., Zahner, G., Harendza, S., Wolf, G., Thaiss, F., Stahl, R.A. Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis. Kidney Int., 2002, 62, 455-464.
17. Einhorn, D., Aroda, V.R., Henry, R.R. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol. Metab. Clin. North Am., 2004, 33, 595-616, vii-viii.
18. Lewin, A.J., Kipnes, M.S., Meneghini, L.F., Plotkin, D.J., Perevozskaya, I.T., Shah, S., Maccubbin, D.L., Mitchel, Y.B., Tobert, J.A. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther., 2004, 26, 379-389.
19. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., Nathan, D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 2002, 346, 393-403.
20. Buchanan, T.A., Xiang, A.H., Peters, R.K., Kjos, S.L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H.N., Azen, S.P. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes, 2002, 51, 2796-2803.
21. Chilcott, J., Tappenden, P., Jones, M.L., Wight, J.P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin. Ther., 2001, 23, 1792-1823; discussion 1791.
22. Kelly, I.E., Han, T.S., Walsh, K., Lean, M.E. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care, 1999, 22, 288-293.
23. Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L.J., DeFronzo, R.A. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 2002, 87, 2784-2791.
24. Avandia (rosiglitazone maleate). Philadelphia, PA, GlaxoSmith Kline Pharmaceuticals, 2000.
25. Raskin, P., Rendell, M., Riddle, M.C., Dole, J.F., Freed, M.I., Rosenstock, J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care, 2001, 24, 1226-1232.
26. Walker, A.B., Naderali, E.K., Chattington, P.D., Buckingham, R.E., Williams, G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes, 1998, 47, 810-814.
27. Nesto, R.W., Bell, D., Bonow, R.O., Fonseca, V., Grundy, S.M., Horton, E.S., Le Winter, M., Porte, D., Semenkovich, C.F., Smith, S., Young, L.H., Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care, 2004, 27, 256-263.